Organovo’s proprietary bioprinting platform captures the unique synergistic potential of engineering and biology to enable the reproducible, automated creation of living human tissues that mimic the form and function of native tissues in the body. Genomics and proteomics have revolutionized research through the creation of highly reproducible tools for studying the genome and proteome.
Organovo’s scientific founder, Gabor Forgacs, presents on bioprinting at TEDMED.
Our goal is to build living human tissues that are proven to function like native tissues for in vitro and therapeutic applications.
Organovo’s exVive3D™ bioprinted human tissues are developed for use in Organomics™, the study of living organs in vitro. Our 3D bioprinted human tissues are constructed with precision from tiny building blocks made of living human cells, using a process that translates tissue-specific geometries and cellular components utilizing the NovoGen Bioprinter™. These bioprinted tissues share many key features with native tissue, including tissue-like cellular density, presence of multiple cell types, and the development of key architectural and functional features associated with the target native tissue.
Significant science and discovery is required to develop a tissue therapy, ensure safety and efficacy through controlled clinical trials, and gain regulatory clearance as a medical device. Supplemental tissue therapies that could come in forms of tubes, patches, or organoids are a developmental possibility today.